High-dose therapy and autologous stem cell transplantation for children with HIV-associated non-Hodgkin lymphoma.
In contrast to adults, autologous stem cell transplantation (ASCT) as part of the salvage strategy after high-dose chemo/radiotherapy in human immunodeficiency virus (HIV) related Non-Hodgkin lymphoma (NHL) is not yet established for children. We report on a 13-year patient with congenital HIV infection and refractory Burkitt lymphoma, who was successfully treated by high-dose therapy (HDT) including rituximab followed by ASCT. After 26 months follow-up the patient remains in complete remission and his HIV parameters have normalized with continued highly active antiretroviral therapy (HAART). HIV infection may no longer exclude children from ASCT as part of salvage therapy.
Fluri
Simon
S
Department of Pediatric Hematology/Oncology, University Children's Hospital, Bern, Switzerland. simon.fluri@insel.ch
Ammann
Roland
R
Lüthy
Annette Ridolfi
AR
Hirt
Andreas
A
Aebi
Christoph
C
Duppenthaler
Andrea
A
Leibundgut
Kurt
K